Literature DB >> 770334

Restoration of T-cell responsiveness by thymosin: development of antituberculous resistance in BCG-infected animals.

N E Morrison, F M Collins.   

Abstract

T-cell-depleted (adult thymectomized, lethally irradiated, bone marrow-reconstituted [THXB]), sham-thymectomized (XB) and normal control mice were injected daily with 3 mg of calf thymosin for 16 days. On day 8 of the treatment, the mice, together with untreated controls, were infected intravenously with 4 X 10(6) viable Mycobacterium bovis (BCG Montreal). Growth of the BCG in the lungs and spleens was compared quantitatively for up to 100 days. Thymosin treatment reversed the progressive weight loss seen in BCG-infected THXB mice and prevented their death due to the ongoing mycobacteriosis that developed in the T-cell-depleted animal. There was a late-developing anti-mycobacterial response in the thymosin-treated THXB mice, which resulted in a progressive decline in viability for the lung and spleen populations over the 40- to 80-day period, when the corresponding counts for the untreated THXB mice remained relatively constant. The histopathology of the lung and the increased antibacterial activity seen in the thymosin-treated THXB mice correlated with decreased [3H]deoxyribonucleic acid levels seen in the lungs and spleen compared with that present in the T-cell-depleted controls.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 770334      PMCID: PMC420646          DOI: 10.1128/iai.13.2.554-563.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  On the mode of action of thymosin.

Authors:  E M Lance; S C Gillette; A L Goldstein; A White; M M Zatz
Journal:  Cell Immunol       Date:  1973-01       Impact factor: 4.868

2.  Importance of thymus-derived lymphocytes in cell-mediated immunity to infection.

Authors:  R J North
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

3.  Immunological control of macrophage proliferation in vivo.

Authors:  R J North; G B Mackaness
Journal:  Infect Immun       Date:  1973-07       Impact factor: 3.441

4.  Influence of thymosin on cell-mediated and humoral immune responses in normal and in immunologically deficient mice.

Authors:  A L Goldstein; Y Asanuma; J R Battisto; M A Hardy; J Quint; A White
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

5.  Experimental lepromatous leprosy.

Authors:  R J Rees; M F Waters; A G Weddell; E Palmer
Journal:  Nature       Date:  1967-08-05       Impact factor: 49.962

Review 6.  The immunology of antituberculous immunity.

Authors:  G B Mackaness
Journal:  Am Rev Respir Dis       Date:  1968-03

7.  Growth of mycobacterium bovis (BCG) in T lymphocyte-depleted mice.

Authors:  F M Collins; C C Congdon; N E Morrison
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

8.  Inflammatory lymphocyte in cell-mediated antibacterial immunity: factors governing the accumulation of mediator T cells in peritoneal exudates.

Authors:  R J North; G Spitalny
Journal:  Infect Immun       Date:  1974-09       Impact factor: 3.441

9.  The relationship of delayed hypersensitivity to acquired antituberculous immunity. I. Tuberculin sensitivity and resistance to reinfection in BCG-vaccinated mice.

Authors:  F M Collins; G B Mackaness
Journal:  Cell Immunol       Date:  1970-09       Impact factor: 4.868

10.  Immunogenicity of an aerogenic BCG vaccine in T-cell-depleted and normal mice.

Authors:  N E Morrison; F M Collins
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

View more
  2 in total

1.  Restoration of delayed hypersensitivity to sheep erythrocytes by thymosin treatment of T-cell-depleted mice.

Authors:  F M Collins; N E Morrison
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

2.  Restoration of T-cell responsiveness by thymosin: expression of anti-tuberculous immunity in mouse lungs.

Authors:  F M Collins; N E Morrison
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.